Zacks Research Has Negative View of Haemonetics Q1 Earnings

Key Points

• Zacks Research has lowered its Q1 2027 earnings per share estimate for Haemonetics to $1.19, down from a previous estimate of $1.20.
• Haemonetics reported an EPS of $1.10 for the previous quarter, exceeding the consensus estimate of $1.01, although revenue declined by 4.4% year-over-year.
• The company's stock is rated an average of "Moderate Buy" by analysts, with a consensus price target of $85.18.

Haemonetics Corporation (NYSE:HAE - Free Report) - Equities researchers at Zacks Research lowered their Q1 2027 earnings per share (EPS) estimates for Haemonetics in a research report issued on Monday, September 8th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $1.19 for the quarter, down from their prior forecast of $1.20. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' FY2027 earnings at $5.23 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.09. The firm had revenue of $321.39 million during the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business's revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.02 earnings per share. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS.

A number of other research analysts also recently weighed in on the company. Raymond James Financial downgraded Haemonetics from a "strong-buy" rating to an "outperform" rating and decreased their price target for the company from $105.00 to $78.00 in a research note on Monday, August 11th. Robert W. Baird started coverage on Haemonetics in a research note on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. Barrington Research reduced their target price on Haemonetics from $95.00 to $86.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Needham & Company LLC reiterated a "buy" rating and set a $68.00 target price (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $62.00 target price (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and a consensus target price of $78.78.

Haemonetics Stock Down 2.3%

HAE stock traded down $1.25 during mid-day trading on Tuesday, reaching $52.23. The company had a trading volume of 1,603,169 shares, compared to its average volume of 886,584. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The stock has a 50 day simple moving average of $63.77 and a two-hundred day simple moving average of $65.38. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 15.97, a PEG ratio of 0.96 and a beta of 0.39. Haemonetics has a 52 week low of $50.68 and a 52 week high of $94.99.

Institutional Trading of Haemonetics

Several hedge funds have recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co lifted its holdings in Haemonetics by 9.6% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 34,172 shares of the medical instruments supplier's stock worth $2,554,000 after purchasing an additional 2,987 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Haemonetics by 331.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,704 shares of the medical instruments supplier's stock worth $649,000 after purchasing an additional 6,687 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in Haemonetics by 13.0% during the 2nd quarter. Corient Private Wealth LLC now owns 5,233 shares of the medical instruments supplier's stock worth $390,000 after purchasing an additional 600 shares during the last quarter. Captrust Financial Advisors lifted its holdings in Haemonetics by 152.7% during the 2nd quarter. Captrust Financial Advisors now owns 11,021 shares of the medical instruments supplier's stock worth $822,000 after purchasing an additional 6,660 shares during the last quarter. Finally, Tidal Investments LLC lifted its holdings in Haemonetics by 72.9% during the 2nd quarter. Tidal Investments LLC now owns 15,194 shares of the medical instruments supplier's stock worth $1,134,000 after purchasing an additional 6,408 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.